Group 1 - The announcement details the pledge and release of shares by the controlling shareholder, Fosun High Technology, which holds approximately 36.00% of the company's total shares as of November 6, 2025 [2][3] - After the pledge and release, the remaining pledged shares by Fosun High Technology amount to 546,925,000 shares, representing about 20.48% of the total shares [2][3] - The total shares held by Fosun High Technology and its concerted parties amount to 967,812,180 shares, which is approximately 36.24% of the company's total shares [2][3] Group 2 - As of November 6, 2025, 36,670,000 pledged shares are expected to mature within the next year, accounting for about 13.73% of the company's total shares, with a corresponding financing balance of RMB 3.431 billion [7] - Fosun High Technology confirms that its operations are normal and it has the ability to repay the financing, with sources including bond issuance and investment returns [7] - The company will closely monitor the progress of the share pledges and fulfill its disclosure obligations as required by laws and regulations [8] Group 3 - The company has scheduled its second extraordinary general meeting for December 2, 2025, with both onsite and online voting options available for shareholders [10][11] - The meeting will be held at Shanghai Tianxi Jiafu Puti Hotel, starting at 13:30 [12] - A detailed voting procedure is provided for A-share shareholders, including registration and voting methods [18][20]

Core Viewpoint - Fosun Pharma showcases its innovative products and global collaborations at the 8th China International Import Expo, highlighting its deep commitment to the global healthcare sector and continuous breakthroughs [1][3]. Group 1: Product Innovation and Localization - Fosun Pharma has successfully localized several innovative products, including the Da Vinci surgical robot and CAR-T cell therapy product Yikaida, benefiting numerous Chinese patients and enhancing industry standards [3]. - The Yikaida product has treated over 1,000 lymphoma patients since its debut at the first Import Expo in 2018, marking significant advancements in commercial insurance and clinical efficacy [3]. - The Da Vinci surgical robot has been installed over 460 times in mainland China and Hong Kong, serving more than 810,000 patients, with new systems showcased this year expanding its capabilities in minimally invasive surgery [3]. Group 2: Infrastructure and Investment - The launch of the Intuitive Medical headquarters in Shanghai, with an investment of approximately 700 million yuan, marks a significant shift for Fosun Pharma from exhibitor to investor, strengthening its local industrial foundation [4]. - The Magnetic Resonance Guided Focused Ultrasound system has been introduced to over ten key medical institutions in China, treating nearly 1,000 patients, with the new V2 model receiving CE and FDA certifications [4]. Group 3: Strategic Collaborations and Global Operations - Fosun Pharma's Marie® upright particle therapy system, recently FDA approved, represents a new approach to tumor treatment, significantly reducing construction and operational costs while accommodating various advanced therapies [6]. - A strategic partnership with Leo Cancer Care aims to accelerate the introduction of this technology in China, enhancing treatment accessibility for cancer patients [8]. - The company employs a dual strategy of "independent research and development + cooperative introduction," focusing on cutting-edge fields such as antibody therapy, ADC, and gene editing [8]. Group 4: International Expansion and Market Presence - Fosun Pharma's internationalization has progressed beyond trade, entering a new phase of "global operations," with over 1,000 overseas commercialization teams established in markets like the US, Europe, and Southeast Asia [8]. - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for 28.07% of total revenue, indicating strong international market penetration [8]. - The company's self-developed PD-1 inhibitor has been approved in nearly 40 countries, establishing a benchmark for "Chinese innovation going global" [8]. Group 5: Industry Impact and Future Outlook - Fosun Pharma's comprehensive global capabilities are reshaping the international competitiveness of Chinese pharmaceutical companies, serving as a model for industry innovation and integration in an era of global adjustment [9].

Core Viewpoint - The Medical Health R Index (480016) closed at 7535.01 points, down 0.39%, with a trading volume of 21.869 billion yuan and a turnover rate of 0.89% on November 7 [1] Group 1: Index Performance - The index had 26 stocks rising, with Xinhecheng leading at a 4.9% increase, while 23 stocks fell, with Zaiqing Pharmaceutical leading the decline at 4.35% [1] - The top ten constituent stocks of the Medical Health R Index are primarily in the pharmaceutical and medical sectors, with notable weights and market capitalizations [1] Group 2: Key Constituents - WuXi AppTec (sh603259) holds a weight of 13.66% with a market cap of 282.98 billion yuan, closing at 94.84 yuan, down 0.89% [1] - Hengrui Medicine (sh600276) has an 11.00% weight, a market cap of 408.72 billion yuan, and closed at 61.58 yuan, down 1.35% [1] - Mindray Medical (sz300760) has a weight of 7.57%, a market cap of 249.51 billion yuan, and closed at 205.79 yuan, down 0.27% [1] - Other notable constituents include United Imaging Healthcare (sh688271), Pianzai Shou (sh600436), and Xinhecheng (sz002001), which saw a 4.9% increase [1] Group 3: Capital Flow - The Medical Health R Index constituents experienced a net outflow of 240 million yuan from institutional investors and 119 million yuan from retail investors, while retail investors saw a net inflow of 359 million yuan [1] - Specific stocks like Huazhong Pharmaceutical (000999) and Yuyue Medical (002223) showed significant net inflows and outflows among different investor types [2]

Core Viewpoint - Fosun Pharma (02196) announced that its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., has pledged and released part of its A-share holdings in the company, indicating ongoing financial maneuvers within the company [1] Group 1 - The controlling shareholder pledged 20 million shares of Fosun Pharma [1] - The controlling shareholder released 85.75 million shares from pledge [1]

Core Viewpoint - The China International Import Expo (CIIE) is significantly accelerating the speed at which innovative drugs enter the Chinese market, transforming the landscape for multinational pharmaceutical companies and benefiting countless patients [3][8]. Group 1: Innovative Drug Launches - A groundbreaking drug for delaying the progression of type 1 diabetes, Trelagliptin, made its Asian debut at the CIIE and received approval for market entry in September [10]. - Sanofi's innovative cardiovascular drugs and Gilead Sciences' long-acting HIV prevention drug, Lenacapavir, were showcased at the CIIE, indicating a trend of faster access to top-tier medications for Chinese patients [6][18]. - The "CIIE speed" is exemplified by Sanofi's drug Dupixent, which received approval in China ahead of the U.S. FDA, showcasing a record time for innovative drugs to benefit Chinese patients [11]. Group 2: Market Strategy and Investment - Multinational pharmaceutical companies are shifting from merely introducing products to deeper, full-industry chain strategies in China, with Sanofi establishing China as an independent strategic market unit [20][22]. - Novartis has conducted over 100 clinical trials in China and aims for 90% of new drug registrations to align with global timelines within the next two years [28]. - Gilead Sciences is focusing on synchronizing its research and development projects in China with global efforts, emphasizing the importance of the Chinese market [23][26]. Group 3: CIIE's Spillover Effect - The CIIE is not only expediting drug launches but also creating a "spillover effect" that enhances the overall healthcare landscape in China, allowing for broader access to innovative treatments [15][17]. - Since its inception, Novartis has had over 40 innovative drugs and indications approved in China, accounting for 40% of its total approvals in the country since 1987 [15]. - The CIIE serves as a high-level open platform that fosters consensus, innovation, and collaboration among pharmaceutical companies, ultimately changing the lives of Chinese patients [17].

Core Viewpoint - Fosun Pharma (600196)(02196) announced that its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., has completed the pledge and release of part of its A-share holdings, indicating active management of its equity position [1] Summary by Category - **Pledge and Release of Shares** - The company reported that 20 million shares were pledged and 85.75 million shares were released from pledge [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 1 月7 日 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年第二次臨時股東會會議資料》，僅供參閱。 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 1 月7 日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 召開2025 年第二次臨時股東會的通知》，僅供參閱。 承董事會命 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * ...

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 股東部分股份質押及解除質押的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 1 月7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-174 上海复星医药（集团）股份有限公司 关于股东部分股份质押及解除质押的公告 ● 截至 2025 年 11 月 6 日收市，控股股东复星高科技及其一致行动人（即 复星高科技董监高、复星国际有限公司及其董高<包括本公司实际控制人>，下同） 合计持有本公司967,812,180股股份（其中：A股890,278,680股、H股77,533,500 股），约占截至当日收市本公司股份总数的 36.24%。本次质押及解除质押后， 复星高科技及其一致行动人质押本公司股份数量余额为 546,925,000 股（均为 A 股），约占复星高科技及其一致行动人所持有本公司股份数的 56.51%。 上海复星医药（集团）股份有限公司（以下简称"本公司"）于 2025 年 11 月 7 日接到控股股东上海复星高科技（集团）有限公司（以下简称"复星高科技"） 的通知，其已将所持有的本公司部分 A 股股份办理质押及解除质押手续，具体如 下： 1 一、部分股份本次质押基本情况 | 股东 | 是否 | 本次质押 | 是否为 | 是否 | 质押 | 质押 | 质权人 | 占其 | ...